(R409H) Cause Metabolic Defects in Primary Cardiac Malignant Tumor
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Tbamitchodral L Alizaion of the 4Aminobutyrate-2-&Oxoglutarate
5d.em. J. (lWg77) 161,9O.-307 3O1 Printed in Great Britain Tbamitchodral L alizaion of the 4Aminobutyrate-2-&Oxoglutarate Transminase from Ox Brait By INGER SCHOUSDOE,* BIRGIT 1MO* and ARNE SCHOUSBOEt Department ofBDahemistry At andC*, University ofCopenhagen, 2200 Copenhagen M, Denark (Receved 4 June 1976) In order to determine the intramitochondrial location of 4-aminobutyrate transaminase, mitochondria were prepared from ox brain and freed from myelin and syiaptosomes by using conventional demitygradient-centrifugation techniques, and the purity was checked electron-microscopically. Iner and outer mimbrenes and matrix were prepared from the mitochondria by large-amplitude sweling and subsequent density-gradient centrfugationt The fractions were characterized by using both electron microscopy and differnt marker enzymes. From the specific activity of the 4-aminobutyrate transaminase in the submitochondrial fractions it was concluded that this enzyme is associated with the inner mitochondrial membrane. It is generally agreed that the 4-aminobutyrate-2- pyridoxal phosphate were from Sigma Chemical oxoglutarate transaminase (EC2.6.1.19) from brain is Co., St. Louis, MO, U.S.A. Ficoll was from mainly associated with free mitochondria (Salganicoff Pharmacia, Uppsala, Sweden, and crystallized & De Robertis, 1963, 1965; van den Berget al., 1965; bovine serum albumin was from BDH Biochemicals, van Kempen et at., 1965; Balazs et al., 1966; Poole, Dorset, U.K. 4-Amino[1-'4C]butyrate (sp. Waksman et al., 1968; Reijnierse et al., 1975), radioactivity 50mCi/mmol) and [1-14qtyramine (sp. and a preparation of a crude mitochondrial fraction radioactivity 9mCi/mmol) were obtained from was used by Schousboe et al. (1973) and Maitre et al. -
Alternative Acetate Production Pathways in Chlamydomonas Reinhardtii During Dark Anoxia and the Dominant Role of Chloroplasts in Fermentative Acetate Productionw
This article is a Plant Cell Advance Online Publication. The date of its first appearance online is the official date of publication. The article has been edited and the authors have corrected proofs, but minor changes could be made before the final version is published. Posting this version online reduces the time to publication by several weeks. Alternative Acetate Production Pathways in Chlamydomonas reinhardtii during Dark Anoxia and the Dominant Role of Chloroplasts in Fermentative Acetate ProductionW Wenqiang Yang,a,1 Claudia Catalanotti,a Sarah D’Adamo,b Tyler M. Wittkopp,a,c Cheryl J. Ingram-Smith,d Luke Mackinder,a Tarryn E. Miller,b Adam L. Heuberger,e Graham Peers,f Kerry S. Smith,d Martin C. Jonikas,a Arthur R. Grossman,a and Matthew C. Posewitzb a Carnegie Institution for Science, Department of Plant Biology, Stanford, California 94305 b Colorado School of Mines, Department of Chemistry and Geochemistry, Golden, Colorado 80401 c Stanford University, Department of Biology, Stanford, California 94305 d Clemson University, Department of Genetics and Biochemistry, Clemson, South Carolina 29634 e Colorado State University, Proteomics and Metabolomics Facility, Fort Collins, Colorado 80523 f Colorado State University, Department of Biology, Fort Collins, Colorado 80523 ORCID ID: 0000-0001-5600-4076 (W.Y.) Chlamydomonas reinhardtii insertion mutants disrupted for genes encoding acetate kinases (EC 2.7.2.1) (ACK1 and ACK2) and a phosphate acetyltransferase (EC 2.3.1.8) (PAT2, but not PAT1) were isolated to characterize fermentative acetate production. ACK1 and PAT2 were localized to chloroplasts, while ACK2 and PAT1 were shown to be in mitochondria. -
Progressive Increase in Mtdna 3243A>G Heteroplasmy Causes Abrupt
Progressive increase in mtDNA 3243A>G PNAS PLUS heteroplasmy causes abrupt transcriptional reprogramming Martin Picarda, Jiangwen Zhangb, Saege Hancockc, Olga Derbenevaa, Ryan Golhard, Pawel Golike, Sean O’Hearnf, Shawn Levyg, Prasanth Potluria, Maria Lvovaa, Antonio Davilaa, Chun Shi Lina, Juan Carlos Perinh, Eric F. Rappaporth, Hakon Hakonarsonc, Ian A. Trouncei, Vincent Procaccioj, and Douglas C. Wallacea,1 aCenter for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; bSchool of Biological Sciences, The University of Hong Kong, Hong Kong, People’s Republic of China; cTrovagene, San Diego, CA 92130; dCenter for Applied Genomics, Division of Genetics, Department of Pediatrics, and hNucleic Acid/Protein Research Core Facility, Children’s Hospital of Philadelphia, Philadelphia, PA 19104; eInstitute of Genetics and Biotechnology, Warsaw University, 00-927, Warsaw, Poland; fMorton Mower Central Research Laboratory, Sinai Hospital of Baltimore, Baltimore, MD 21215; gGenomics Sevices Laboratory, HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806; iCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia; and jDepartment of Biochemistry and Genetics, National Center for Neurodegenerative and Mitochondrial Diseases, Centre Hospitalier Universitaire d’Angers, 49933 Angers, France Contributed by Douglas C. Wallace, August 1, 2014 (sent for review May -
Mutation of the Fumarase Gene in Two Siblings with Progressive Encephalopathy and Fumarase Deficiency T
Mutation of the Fumarase Gene in Two Siblings with Progressive Encephalopathy and Fumarase Deficiency T. Bourgeron,* D. Chretien,* J. Poggi-Bach, S. Doonan,' D. Rabier,* P. Letouze,I A. Munnich,* A. R6tig,* P. Landneu,* and P. Rustin* *Unite de Recherches sur les Handicaps Genetiques de l'Enfant, INSERM U393, Departement de Pediatrie et Departement de Biochimie, H6pital des Enfants-Malades, 149, rue de Sevres, 75743 Paris Cedex 15, France; tDepartement de Pediatrie, Service de Neurologie et Laboratoire de Biochimie, Hopital du Kremlin-Bicetre, France; IFaculty ofScience, University ofEast-London, UK; and IService de Pediatrie, Hopital de Dreux, France Abstract chondrial enzyme (7). Human tissue fumarase is almost We report an inborn error of the tricarboxylic acid cycle, fu- equally distributed between the mitochondria, where the en- marase deficiency, in two siblings born to first cousin parents. zyme catalyzes the reversible hydration of fumarate to malate They presented with progressive encephalopathy, dystonia, as a part ofthe tricarboxylic acid cycle, and the cytosol, where it leucopenia, and neutropenia. Elevation oflactate in the cerebro- is involved in the metabolism of the fumarate released by the spinal fluid and high fumarate excretion in the urine led us to urea cycle. The two isoenzymes have quite homologous struc- investigate the activities of the respiratory chain and of the tures. In rat liver, they differ only by the acetylation of the Krebs cycle, and to finally identify fumarase deficiency in these NH2-terminal amino acid of the cytosolic form (8). In all spe- two children. The deficiency was profound and present in all cies investigated so far, the two isoenzymes have been found to tissues investigated, affecting the cytosolic and the mitochon- be encoded by a single gene (9,10). -
Pharmacological Inhibition of Tumor Anabolism and Host Catabolism As A
www.nature.com/scientificreports OPEN Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy Alejandro Schcolnik‑Cabrera1,2, Alma Chavez‑Blanco1, Guadalupe Dominguez‑Gomez1, Mandy Juarez1, Ariana Vargas‑Castillo3, Rafael Isaac Ponce‑Toledo4, Donna Lai5, Sheng Hua5, Armando R. Tovar3, Nimbe Torres3, Delia Perez‑Montiel6, Jose Diaz‑Chavez1 & Alfonso Duenas‑Gonzalez1,7* The malignant energetic demands are satisfed through glycolysis, glutaminolysis and de novo synthesis of fatty acids, while the host curses with a state of catabolism and systemic infammation. The concurrent inhibition of both, tumor anabolism and host catabolism, and their efect upon tumor growth and whole animal metabolism, have not been evaluated. We aimed to evaluate in colon cancer cells a combination of six agents directed to block the tumor anabolism (orlistat + lonidamine + DON) and the host catabolism (growth hormone + insulin + indomethacin). Treatment reduced cellular viability, clonogenic capacity and cell cycle progression. These efects were associated with decreased glycolysis and oxidative phosphorylation, leading to a quiescent energetic phenotype, and with an aberrant transcriptomic landscape showing dysregulation in multiple metabolic pathways. The in vivo evaluation revealed a signifcant tumor volume inhibition, without damage to normal tissues. The six‑drug combination preserved lean tissue and decreased fat loss, while the energy expenditure got decreased. Finally, a reduction in gene expression associated with thermogenesis was observed. Our fndings demonstrate that the simultaneous use of this six‑drug combination has anticancer efects by inducing a quiescent energetic phenotype of cultured cancer cells. Besides, the treatment is well‑ tolerated in mice and reduces whole animal energetic expenditure and fat loss. -
Robert Shine, Peter Dwyer, Lyndsay Olson, Jennifer Truong, Matthew Goddeeris, Effie Tozzo, Eric Bell Mitobridge, Inc
Poster Title Here Mitochondrial Deficiency in Primary Muscle Cells from Mdx Mice Robert Shine, Peter Dwyer, Lyndsay Olson, Jennifer Truong, Matthew Goddeeris, Effie Tozzo, Eric Bell Mitobridge, Inc. Cambridge, MA 02138 Abstract Results Results Duchenne muscular dystrophy (DMD) is a recessive, fatal X-linked disease that is characterized M ito c h o n d ria l c o n trib u te d A T P is re d u c e d Mdx myoblasts have decreased expression by progressive skeletal muscle wasting due to a loss of function in dystrophin, a protein that is of OXPHOS complexes part of a complex that bridges the cytoskeleton and extracellular matrix. The mdx mouse, an in m d x m y o b la s ts a n d m y o tu b e s T animal model for DMD, has a point mutation in the dystrophin gene that results in a loss of 1 .5 2.0 W l function. This study uses primary muscle satellite cell derived myoblasts and myotubes to W T a WT m determine differences in mitochondrial biology between the mdx mice and wild type (WT) control s M D X o 1.5 a r MDX mice. Compared to cells isolated from WT mice, mdx cells have reductions in mitochondrial 1 .0 **** f B bioenergetics. Moreover, mdx cells have reduced levels of mitochondria which may partially *** e T g 1.0 explain the reduction in bioenergetics. Interestingly, the mitochondrial phenotype is apparent **** ** n * * W a * * * before dystrophin protein is increased during myogenesis. * * * 0 .5 h 0.5 * d l C o d l F 0.0 o 1 3 2 6 1 a 1 a b B 0 .0 F t v Materials and Analysis a 5 P X D C H H y 5 l l F X T N R O D a M in a M in D C s s P n n U A c c O S C C a 0 a 0 S y y T B 0 B 0 D WT and mdx myoblast isolation and culture: Quadricep and gastrocnemius muscles from a C 1 m 1 m Q A o o N single mouse were pooled and subjected to a mechanical/collagenase digestion. -
Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments. -
Citric Acid Cycle
CHEM464 / Medh, J.D. The Citric Acid Cycle Citric Acid Cycle: Central Role in Catabolism • Stage II of catabolism involves the conversion of carbohydrates, fats and aminoacids into acetylCoA • In aerobic organisms, citric acid cycle makes up the final stage of catabolism when acetyl CoA is completely oxidized to CO2. • Also called Krebs cycle or tricarboxylic acid (TCA) cycle. • It is a central integrative pathway that harvests chemical energy from biological fuel in the form of electrons in NADH and FADH2 (oxidation is loss of electrons). • NADH and FADH2 transfer electrons via the electron transport chain to final electron acceptor, O2, to form H2O. Entry of Pyruvate into the TCA cycle • Pyruvate is formed in the cytosol as a product of glycolysis • For entry into the TCA cycle, it has to be converted to Acetyl CoA. • Oxidation of pyruvate to acetyl CoA is catalyzed by the pyruvate dehydrogenase complex in the mitochondria • Mitochondria consist of inner and outer membranes and the matrix • Enzymes of the PDH complex and the TCA cycle (except succinate dehydrogenase) are in the matrix • Pyruvate translocase is an antiporter present in the inner mitochondrial membrane that allows entry of a molecule of pyruvate in exchange for a hydroxide ion. 1 CHEM464 / Medh, J.D. The Citric Acid Cycle The Pyruvate Dehydrogenase (PDH) complex • The PDH complex consists of 3 enzymes. They are: pyruvate dehydrogenase (E1), Dihydrolipoyl transacetylase (E2) and dihydrolipoyl dehydrogenase (E3). • It has 5 cofactors: CoASH, NAD+, lipoamide, TPP and FAD. CoASH and NAD+ participate stoichiometrically in the reaction, the other 3 cofactors have catalytic functions. -
Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: an Update
International Journal of Molecular Sciences Review Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update Philippe Icard 1,2,3,*, Antoine Coquerel 1,4, Zherui Wu 5 , Joseph Gligorov 6, David Fuks 7, Ludovic Fournel 3,8, Hubert Lincet 9,10 and Luca Simula 11 1 Medical School, Université Caen Normandie, CHU de Caen, 14000 Caen, France; [email protected] 2 UNICAEN, INSERM U1086 Interdisciplinary Research Unit for Cancer Prevention and Treatment, Normandie Université, 14000 Caen, France 3 Service de Chirurgie Thoracique, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, APHP, Paris-Descartes University, 75014 Paris, France; [email protected] 4 INSERM U1075, COMETE Mobilités: Attention, Orientation, Chronobiologie, Université Caen, 14000 Caen, France 5 School of Medicine, Shenzhen University, Shenzhen 518000, China; [email protected] 6 Oncology Department, Tenon Hospital, Pierre et Marie Curie University, 75020 Paris, France; [email protected] 7 Service de Chirurgie Digestive et Hépato-Biliaire, Hôpital Cochin, Hôpitaux Universitaires Paris Centre, APHP, Paris-Descartes University, 75014 Paris, France; [email protected] 8 Descartes Faculty of Medicine, University of Paris, Paris Center, 75006 Paris, France 9 INSERM U1052, CNRS UMR5286, Cancer Research Center of Lyon (CRCL), 69008 Lyon, France; [email protected] 10 ISPB, Faculté de Pharmacie, Université Lyon 1, 69373 Lyon, France 11 Department of Infection, Immunity and Inflammation, Institut Cochin, INSERM U1016, CNRS UMR8104, Citation: Icard, P.; Coquerel, A.; Wu, University of Paris, 75014 Paris, France; [email protected] Z.; Gligorov, J.; Fuks, D.; Fournel, L.; * Correspondence: [email protected] Lincet, H.; Simula, L. -
PIM2-Mediated Phosphorylation of Hexokinase 2 Is Critical for Tumor Growth and Paclitaxel Resistance in Breast Cancer
Oncogene (2018) 37:5997–6009 https://doi.org/10.1038/s41388-018-0386-x ARTICLE PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer 1 1 1 1 1 2 2 3 Tingting Yang ● Chune Ren ● Pengyun Qiao ● Xue Han ● Li Wang ● Shijun Lv ● Yonghong Sun ● Zhijun Liu ● 3 1 Yu Du ● Zhenhai Yu Received: 3 December 2017 / Revised: 30 May 2018 / Accepted: 31 May 2018 / Published online: 9 July 2018 © The Author(s) 2018. This article is published with open access Abstract Hexokinase-II (HK2) is a key enzyme involved in glycolysis, which is required for breast cancer progression. However, the underlying post-translational mechanisms of HK2 activity are poorly understood. Here, we showed that Proviral Insertion in Murine Lymphomas 2 (PIM2) directly bound to HK2 and phosphorylated HK2 on Thr473. Biochemical analyses demonstrated that phosphorylated HK2 Thr473 promoted its protein stability through the chaperone-mediated autophagy (CMA) pathway, and the levels of PIM2 and pThr473-HK2 proteins were positively correlated with each other in human breast cancer. Furthermore, phosphorylation of HK2 on Thr473 increased HK2 enzyme activity and glycolysis, and 1234567890();,: 1234567890();,: enhanced glucose starvation-induced autophagy. As a result, phosphorylated HK2 Thr473 promoted breast cancer cell growth in vitro and in vivo. Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo. Taken together, our findings indicated that PIM2 was a novel regulator of HK2, and suggested a new strategy to treat breast cancer. Introduction ATP molecules. -
Ketoconazole and Posaconazole Selectively Target HK2-Expressing Glioblastoma Cells
Published OnlineFirst October 15, 2018; DOI: 10.1158/1078-0432.CCR-18-1854 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells Sameer Agnihotri1, Sheila Mansouri2, Kelly Burrell2, Mira Li2, Mamatjan Yasin, MD2, Jeff Liu2,3, Romina Nejad2, Sushil Kumar2, Shahrzad Jalali2, Sanjay K. Singh2, Alenoush Vartanian2,4, Eric Xueyu Chen5, Shirin Karimi2, Olivia Singh2, Severa Bunda2, Alireza Mansouri7, Kenneth D. Aldape2,6, and Gelareh Zadeh2,7 Abstract Purpose: Hexokinase II (HK2) protein expression is eleva- in vivo. Treatment of mice bearing GBM with ketoconazole ted in glioblastoma (GBM), and we have shown that HK2 and posaconazole increased their survival, reduced tumor could serve as an effective therapeutic target for GBM. Here, we cell proliferation, and decreased tumor metabolism. In interrogated compounds that target HK2 effectively and addition, treatment with azoles resulted in increased pro- restrict tumor growth in cell lines, patient-derived glioma stem portion of apoptotic cells. cells (GSCs), and mouse models of GBM. Conclusions: Overall, we provide evidence that azoles exert Experimental Design: We performed a screen using a set of their effect by targeting genes and pathways regulated by HK2. 15 drugs that were predicted to inhibit the HK2-associated These findings shed light on the action of azoles in GBM. gene signature. We next determined the EC50 of the com- Combined with existing literature and preclinical results, these pounds by treating glioma cell lines and GSCs. Selected data support the value of repurposing azoles in GBM clinical compounds showing significant impact in vitro were used to trials. -
Complex Hereditary Spastic Paraplegia Associated with Episodic
Tozawa et al. Human Genome Variation (2021) 8:4 https://doi.org/10.1038/s41439-021-00136-y Human Genome Variation DATA REPORT Open Access Complex hereditary spastic paraplegia associated with episodic visual loss caused by ACO2 variants Takenori Tozawa1,2,AkiraNishimura3, Tamaki Ueno2,4, Akane Shikata5, Yoshihiro Taura1,TakeshiYoshida 6, Naoko Nakagawa7, Takahito Wada 7, Shinji Kosugi7, Tomoko Uehara8, Toshiki Takenouchi 9, Kenjiro Kosaki8 and Tomohiro Chiyonobu1 Abstract Most patients with homozygous or compound heterozygous pathogenic ACO2 variants present with muscular hypotonia features, namely, infantile cerebellar-retinal degeneration. Recently, two studies reported rare familial cases of ACO2 variants presenting as complex hereditary spastic paraplegia (HSP) with broad clinical spectra. Here, we report the case of a 20-year-old Japanese woman with complex HSP caused by compound heterozygous ACO2 variants, revealing a new phenotype of episodic visual loss during febrile illness. The ACO2 gene on chromosome 22 encodes the aco- variants in the ACO2 gene presenting as complex her- nitase 2 (ACO2) protein in the mitochondrial matrix; editary spastic paraplegia (HSP) with a new phenotype of ACO2 catalyzes the stereospecific isomerization of citrate episodic visual loss after every febrile infection and pro- to isocitrate in the tricarboxylic acid (TCA) cycle1. gressive optic atrophy. This is the third familial report and ACO2 fi fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Pathogenic variants were rst reported in eight the rst Asian patient with complex HSP caused by individuals from two Arab families, and they had infantile pathogenic ACO2 variants. cerebellar-retinal degeneration (ICRD, OMIM#614559)2. The proband was born to nonconsanguineous healthy Subsequently, ~20 cases of pathogenic homozygous or parents at 38 weeks gestational age after unremarkable compound heterozygous ACO2 variants have been delivery.